La Jolla® Pharmaceutical Company, headquartered in San Diego, CA, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies intended to improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™
(angiotensin II), La Jolla's first commercialized product, was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2017 for adults with septic or other distributive shock.
In accordance with its vision and core values, La Jolla is committed to supporting patients, caregivers, and the entire healthcare professional community.
To learn more about GIAPREZA™, please visit www.giapreza.com.
To learn more about the Medical Affairs department, please visit www.ljpcmedicalaffairs.com.
Ortoleva, Jamel P. et al. A Systematic Approach to the Treatment of Vasoplegia Based on Recent Advances in Pharmacotherapy J Cardiothorac Vasc Anesth, 2018; 33(5): 1310 - 1314
Tumlin JA, Murugan, R Deane AM, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018; 46(6): 949-957
CME / ABIM MOC / CE certified education
Best Practices in Shock-Related Hypotension Management
Authors: Kameron Ferdowsali, MD; Laurence W. Busse, MD; Michael Seneff MD; Kianoush B. Kashani, MD
Valid for credit through: 12/20/2019
NOTE: Medscape is a free educational website. If you are not already a Medscape member, you will be prompted to self-select a free username and password.